Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
07 December, 2021 14:02 IST
Sun Pharma: Reaping the fruits of enhanced efforts in Specialty
Source: IRIS | 13 Oct, 2021, 05.14PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

After having toughed out for more than three years in the US, Sun Pharmaceutical’s flagship product Ilumya is continuously ramping-up sales. While Ilumya and Winlevi contribution can drive growth in Specialty sales over the medium term, SUNP has four products under clinical trials, stated Motilal Oswal Institutional Equities.

The risk to Cequa's sales persist, with scope for genericization of peer product Restasis. SUNP has been able to counter the price erosion in the base business with new product launches and better supply chain management, it said.

Motilal Oswal Institutional Equities has maintained 'Buy' on Sun Pharmaceutical with target price of Rs 960.

While FY15-20 sale CAGR in DF has been muted at 7.7%, SUNP has upped its effort with better performance (14.3% YoY) over the past one year. "Overall, we expect 16% earnings CAGR over FY21-23E, led by a 15%/13% revenue growth in the US/DF. We value SUNP on a 25x 12-months forward earnings basis to arrive at our TP of Rs 960. We maintain our Buy rating," the broking firm added.

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.

 Post Comment
Name Email
Security Code type    into this box
Related Articles
Paints sector, immune from inflation and competition: IDBI Capital -
ICICI Bank: Growing franchise through technological innovations -
Government spends only a third of targeted capex in 1HFY22 -
Domestic 2W market continues to exhibit weakness due to subdued demand -
Banks credit growth may see significant recovery in FY22 -
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer